SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001640455-21-000110
Filing Date
2021-06-22
Accepted
2021-06-22 16:45:43
Documents
2
Period of Report
2021-06-18

Document Format Files

Seq Description Document Type Size
1 FORM 4 wf-form4_162439469478970.html 4  
1 FORM 4 wf-form4_162439469478970.xml 4 4201
2 EXHIBIT 24 - DUNCAN LIMITED POWER OF ATTORNEY ex-24.htm EX-24 4370
  Complete submission text file 0001640455-21-000110.txt   9957
Mailing Address C/O INTERCEPT PHARMACEUTICALS, INC. 18 DESBROSSES STREET NEW YORK NY 10013
Business Address
Duncan Barbara Gayle (Reporting) CIK: 0001353128 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37998 | Film No.: 211035915

Mailing Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139 857-259-3840
Jounce Therapeutics, Inc. (Issuer) CIK: 0001640455 (see all company filings)

IRS No.: 454870634 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)